| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8722700 | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jul, 2023
(2 months ago) | |
| US8299116 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(2 months ago) | |
| US8455539 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(2 months ago) | |
|
US8722700 (Pediatric) | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jan, 2024
(4 months from now) | |
|
US8299116 (Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(4 months from now) | |
|
US8455539 (Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(4 months from now) | |
| US8026276 | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jan, 2026
(2 years from now) | |
|
US8026276 (Pediatric) | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jul, 2026
(2 years from now) | |
| US8791097 | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
May, 2032
(8 years from now) | |
|
US8791097 (Pediatric) | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
Nov, 2032
(9 years from now) | |
Torisel is owned by Pf Prism Cv.
Torisel contains Temsirolimus.
Torisel has a total of 10 drug patents out of which 3 drug patents have expired.
Expired drug patents of Torisel are:
- US8722700
- US8299116
- US8455539
Torisel was authorised for market use on 30 May, 2007.
Torisel is available in solution;intravenous dosage forms.
Torisel can be used as method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; method of treating metastatic papillary renal cell carcinoma with temsirolimus..
The generics of Torisel are possible to be released after 10 November, 2032.
Drugs and Companies using TEMSIROLIMUS ingredient
Market Authorisation Date: 30 May, 2007
Treatment: Method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; Method of treating metastatic papillary renal cell carcinoma with temsirolimus.
Dosage: SOLUTION;INTRAVENOUS
TORISEL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic